Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
about
Targeting the adaptive molecular landscape of castration-resistant prostate cancerIntegrative clinical genomics of advanced prostate cancer.The Molecular Taxonomy of Primary Prostate Cancer.Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.Frequent mismatch-repair defects link prostate cancer to Lynch syndromeGlobal analysis of H3K27me3 as an epigenetic marker in prostate cancer progressionSystematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancerGenomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate TumorsInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.Translational and clinical implications of the genetic landscape of prostate cancer.Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer.Intratumoral heterogeneity of intrahepatic cholangiocarcinoma.Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostateImmunotherapy of Prostate Cancer: Facts and Hopes.Prospects for the use of ipilimumab in treating advanced prostate cancer.Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.Long non-coding RNA ATB promotes growth and epithelial-mesenchymal transition and predicts poor prognosis in human prostate carcinoma.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.The molecular underpinnings of prostate cancer: impacts on management and pathology practice.Treatment strategies for DNA repair-deficient prostate cancer.A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.Applying Ancestry and Sex Computation as a Quality Control Tool in Targeted Next-Generation Sequencing.Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids.Mapping the STK4/Hippo signaling network in prostate cancer cell.LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.Longitudinal analysis of treatment-induced genomic alterations in gliomas.Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.MSH2 Loss in Primary Prostate Cancer.The molecular biology of prostate cancer: current understanding and clinical implications.Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.Genetic mechanisms of immune evasion in colorectal cancer.Mismatch repair enzyme expression in primary and castrate resistant prostate cancer.Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification.Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.Microsatellite instability in prostate cancer by PCR or next-generation sequencing.
P2860
Q27022821-44EDC56F-091B-4AB3-8039-3D92E6C11A37Q27853170-F4FF7ED2-04A4-444B-AADF-702E1DCDF9A3Q34674332-B7EEF75A-2C83-42C6-B009-5744C1299336Q35407284-2D58D44C-2D98-4944-803A-E0B7627DEA9CQ35969934-E2327343-A3C7-4006-BC49-8B87C10DE554Q36345181-2308B493-FD6D-4E4D-A5CD-3CC8EDD37838Q36545434-CF192C89-CC00-4B41-9380-BF2C205C4363Q36646352-9F8FFA89-BFF9-40C8-BE1F-4F774214C526Q36891144-660395AB-DDF6-48C7-B53C-779999D65F87Q37179254-E3A13CEB-0221-4FE7-B128-ECCAAA3D5B0FQ37270512-1C3949C6-2318-4949-B4D4-0CB8A4D609C5Q37302524-1342225D-5AE0-4C87-BCE9-B4C27065F620Q37701535-C40AB482-6F19-489B-9396-40376AA396F3Q37716471-0EFA2A73-4430-43D2-B59A-21EC025116FAQ38377884-DA6B68DF-5B82-46C8-91DE-89ED33478584Q38664882-0519E659-C0CB-4E0A-956F-6EB87ED2EB80Q38677420-240BB925-C55E-4822-B9A9-1B44C1D37D9DQ38768101-1B4BD5E2-1ABA-4AE0-8EB2-AB51B46C1BFAQ38771232-F01C2B69-E8D1-47D9-B62D-B45CCC01F536Q38774228-A73E6105-CEC2-4BA6-8DA9-B3330708C9FFQ38797560-42D8FB93-1412-4529-AE59-A9E43D1A42D1Q38983790-83575184-3524-4C9C-BC49-318E0A4D3390Q39345771-39D241C5-924A-446B-912D-888B0806102AQ39775985-A1DE911E-49B5-48DA-9F8A-631ED0B336BFQ39813483-5D58AEC0-A370-46EE-845C-9273154AF862Q39870818-A8E7D476-674B-47DE-8F9C-9894A1BC4F0AQ41569513-53303CFC-8A96-456D-8983-53F38E2763D5Q42315779-3A1921E5-2BCB-4717-B415-8128A2487F2AQ42324248-E4C02EC7-7071-42E1-9868-88B009E2FCE7Q42324670-06F8D0D6-92E1-438E-A637-AFB8EFBC8FA8Q47725386-54D7B93F-5222-4512-A323-E69A724A889AQ47976701-965C5559-A95B-4AB6-90EB-05A049F432F6Q49546811-6830CB11-6988-4A01-B7C5-33699A3F9C91Q50030814-CA3A92BF-439D-4C0F-A3FD-56574243921EQ50420634-66CD6915-3EB1-417B-871C-A2685E7B9FE6Q51789451-5AF6BD18-39D4-46D1-9354-3B04E75CC622Q52566012-94F76274-5257-4773-B6AA-1F8400DC2A55Q52629153-C87512CA-BED4-4DA8-BAB6-0050D8893E9FQ55172706-6B96EA63-D5F9-4A05-BACA-7A3BA31B13F1Q55264193-D5175C9D-2DE5-4CAD-9301-A3E8B0C61004
P2860
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@ast
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@en
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@nl
type
label
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@ast
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@en
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@nl
prefLabel
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@ast
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@en
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@nl
P2093
P2860
P356
P1476
Complex MSH2 and MSH6 mutation ...... table advanced prostate cancer
@en
P2093
Akash Kumar
Christina Smith
Colin C Pritchard
Colm Morrissey
Ilsa Coleman
Jennifer Milbank
Jonathan F Tait
Peter S Nelson
P2860
P2888
P356
10.1038/NCOMMS5988
P407
P577
2014-09-25T00:00:00Z
P5875
P6179
1009369436